This is the authors' abstract. We don't add key points for this paper.
After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. (Funded by the Advanced Clinical Research Organization and the Japan Breast Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, UMIN000000843 .).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Masuda et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: